Drug Interactions between Malarone and tafenoquine
This report displays the potential drug interactions for the following 2 drugs:
- Malarone (atovaquone/proguanil)
- tafenoquine
Interactions between your drugs
No interactions were found between Malarone and tafenoquine. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Malarone
A total of 124 drugs are known to interact with Malarone.
- Malarone is in the drug class antimalarial combinations.
- Malarone is used to treat the following conditions:
tafenoquine
A total of 36 drugs are known to interact with tafenoquine.
- Tafenoquine is in the drug class antimalarial quinolines.
- Tafenoquine is used to treat the following conditions:
Drug and food interactions
atovaquone food
Applies to: Malarone (atovaquone / proguanil)
ADJUST DOSING INTERVAL: Food, particularly high-fat food, significantly enhances the oral absorption and bioavailability of atovaquone. In 16 healthy volunteers, administration of a single 750 mg dose of atovaquone suspension following a standard breakfast (23 g fat: 610 kCal) resulted in an approximately 3.4-fold increase in the mean peak plasma concentration (Cmax) and a 2.5-fold increase in the mean area under the plasma concentration-time curve (AUC) of atovaquone compared to administration following an overnight fast. In a study consisting of 19 HIV-infected volunteers receiving atovaquone suspension 500 mg/day, Cmax and AUC of atovaquone increased by 72% and 66%, respectively, in the fed state relative to the fasting state.
MANAGEMENT: To ensure maximal oral absorption, atovaquone products (suspension, tablet, or in combination with proguanil) should be administered with a meal or milky drink, or enteral nutrition at the same time(s) each day. Because plasma atovaquone concentrations have been shown to correlate with the likelihood of successful treatment and in some cases, survival, alternative therapies may be appropriate for patients who have difficulty taking atovaquone with food.
References (3)
- (2001) "Product Information. Mepron (atovaquone)." Glaxo Wellcome
- (2001) "Product Information. Malarone (atovaquone-proguanil)." Glaxo Wellcome
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
tafenoquine food
Applies to: tafenoquine
ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of tafenoquine. According to the manufacturer, tafenoquine peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 31% and 41%, respectively, when administered as an investigational capsule formulation with a high-calorie, high-fat meal (approximately 1000 calories; 15% protein, 25% carbohydrate, 60% fat) relative to the fasted state.
MANAGEMENT: Tafenoquine should be administered with food.
References (1)
- (2018) "Product Information. Krintafel (tafenoquine)." GlaxoSmithKline
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Antimalarials
Therapeutic duplication
The recommended maximum number of medicines in the 'antimalarials' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'antimalarials' category:
- Malarone (atovaquone/proguanil)
- tafenoquine
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.